Matching ADHD Medication to the Individual Patient

"Matching ADHD Medication to the Individual Patient" returns to the exam room, where the panel explains how to match a specific ADHD medication to a specific patient's daily reality.

The panel outlines two guiding priorities for matching ADHD medication to the individual patient. First, providers must never accept a patient's "fine" at face value, instead probing for the real-life scenarios and scaffolding that quietly mask ongoing symptoms. Second, providers need to understand that ADHD medications are not interchangeable, since differences in how each is built predict how a given patient will likely experience it, allowing providers to match a specific option to a patient's actual context. One panelist returns to the glasses analogy raised earlier: patients would never settle for 60% corrected vision when 90% is available, and the same logic should guide ADHD treatment rather than accepting partial symptom control as good enough.

The panel recommends getting directly to the point with medicated patients rather than opening with generic small talk, and considers "what is the hardest time of your day" one of the most revealing questions a provider can ask, since it can uncover a side effect, undertreatment, or an unrecognized comorbidity. On side effects, extended-release formulations generally carry the same risk profile as immediate-release options, including reduced appetite, a hard comedown, and blunted personality, though newer formulations aim to reduce how often patients actually experience them. The panel distinguishes severe food aversion from a milder reduced appetite that still allows enjoying a favorite meal, since both technically count as appetite suppression but affect patients very differently.

The panel stresses that the first day on a new medication is typically the hardest, and that feeling nothing at all is usually a sign the dose needs to increase, not that the medication has failed. Patients need to reach their provider within days, not weeks, of starting treatment, since a four-to-six-week wait for follow-up often leads patients to quietly stop a medication that only needed adjustment.

In "Titrating ADHD Medication to an Optimal Dose," the panelists get specific about how aggressively to titrate dosing once treatment begins.